Curis price to sales ratio CRIS
Market value divided by revenue over the last twelve months, since 2012.
- Today, Nov 2, 2026
- 0.3×
- 10-year median
- 6.3×
- Against its 10-year history
- 1st
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 0.2× to 128×
- Peer median
- 35.9×
Curis' price to sales ratio is 0.3× as of Nov 2, 2026.
That is below its ten-year median of 6.3×, lower than on 99% of days in the last ten years.
Over that time it ranged from 0.2× in Oct 2026 to 128× in May 2021.
The median for 10 biotech stocks of a similar size is 35.9×.
Price to sales ratio over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.3× | 0.2× | 3.1× |
| 2025 | 1.2× | 0.9× | 3.2× |
| 2024 | 2.7× | 2.5× | 9.9× |
| 2023 | 7.4× | 2.3× | 9.0× |
| 2022 | 5.1× | 4.6× | 31.7× |
| 2021 | 41.4× | 39.0× | 128× |
| 2020 | 43.4× | 2.4× | 43.4× |
| 2019 | 5.4× | 2.7× | 8.6× |
| 2018 | 2.3× | 2.3× | 13.9× |
| 2017 | 12.8× | 12.8× | 61.0× |
| 2016 | 59.6× | 23.4× | 65.3× |
| 2015 | 48.0× | 12.6× | 49.4× |
| 2014 | 11.8× | 7.1× | 18.7× |
| 2013 | 15.9× | 7.6× | 44.4× |
| 2012 | 9.3× | 8.3× | 17.1× |
Against its peers
Companies in Biotechnology nearest Curis' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| CRISCuris | 0.3× |
| CLDICalidi Biotherapeutics | n/m |
| VIVSVivoSim Labs, INC. | 20.3× |
| SLXNSilexion Therapeutics | n/m |
| PMCBPharmaCyte Biotech | n/a |
| LIMNLiminatus Pharma | n/m |
| CELZCreative Medical Technology | n/m |
| AIMAIM ImmunoTech | 51.5× |
| SNTISenti Biosciences | n/m |
| INABIN8BIO | n/m |
| PASGPassage BIO | n/m |
| Peer median | 35.9× |
Where Curis ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Curis
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.